Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory drugs are a prime example for proximity-induced ph...
Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory drugs are a prime example for proximity-induced ph...
Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory drugs are a prime example for proximity-induced ph...
Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory drugs are a prime example for proximity-induced ph...
Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory drugs are a prime example for proximity-induced ph...
Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory or PROTAC drugs are a prime example for proximity-...
A chemoproteomics experiment was performed to investigate the selectivity of the WDR5 targeting compound LH168. Therefore, a biotinylated adduct of LH168, namely LH205, was used to enrich potential target proteins of LH168. The addition of LH168 in excess competed only the interaction with LH168, de...
SM311 is a covalent LIMK1 inhibitor. To verify the specificity of SM311 towards LIMK1, a chemoproteomic competition experiment was set up with a biotin adduct of SM311, namely SM429. This adduct was immobilised on Streptactin beads and used to enrich proteins binding to SM429. Preincubation with an ...
Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory or PROTAC drugs are a prime example for proximity-...
